Skip to main content

Table 1 Vaccine data for Thailand, based on seven criteria developed from a best–worst scaling (BWS) study

From: What criteria do decision makers in Thailand use to set priorities for vaccine introduction?

Criterion Unit Vaccine
JE [27, 28, 3739] HepBa [17, 27, 28, 39, 40] Hib [27, 28, 39, 41, 42] Rotavirus [27, 28, 39, 43, 44] PCV-13 [27, 28, 39, 45, 46]
Burden of disease Annual incidence per 100,000 population 15–18 6,000–8,000 3.8 33,578 11–29
Target group Age 18–24 months 0–6 months <5 years 0–5 years <5 years
Budget impact Baht per year 239,677,298 355,644,870 1,443,565,660 1,041,994,995 5,121,681,482
Side effect % of fever 1–2 1–6 2–10 0 33
Severity of disease n/a Death (10–20 %); two-thirds of survivors are left with permanent neuropsychiatric sequelae Hepatocellular carcinoma Death, disability Not severe Invasive pneumococcal disease (meningitis, bacteremia)
Effectiveness % 84.8 80 95 70–85 89
Cost of vaccine Baht per course 291 432 1,753 1,265 6,208
Registration year n/a 2002 2000 1998 2008 2010
  1. aThis scenario included HepB vaccine at birth and DTP–HepB vaccine at 2, 4 and 6 months, as recommended in the Thai EPI
  2. JE: Japanese encephalitis; HepB: hepatitis B; Hib: Haemophilus influenzae type B; PCV-13: pneumococcal conjugate vaccine